Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

GILEAD Aktie

 >GILEAD Aktienkurs 
114.42 EUR    -0.5%    (TradegateBSX)
Ask: 113.8 EUR / 80 Stück
Bid: 113.68 EUR / 80 Stück
Tagesumsatz: 1657 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
GILEAD Aktie über LYNX handeln
>GILEAD Performance
1 Woche: -5,5%
1 Monat: +3,6%
3 Monate: +2,9%
6 Monate: -0,5%
1 Jahr: +18,6%
laufendes Jahr: +7,9%
>GILEAD Aktie
Name:  GILEAD SCIENCES DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US3755581036 / 885823
Symbol/ Ticker:  GIS (Frankfurt) / GILD (NASDAQ)
Kürzel:  FRA:GIS, ETR:GIS, GIS:GR, NASDAQ:GILD
Index:  S&P500, Nasdaq100
Profil:  Gilead Sciences Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious and life-threatening diseases. The company’s core franchise centers on therapies for HIV and viral h..
>Volltext..
Marktkapitalisierung:  141229.34 Mio. EUR
Unternehmenswert:  151859.15 Mio. EUR
Umsatz:  26201.96 Mio. EUR
EBITDA:  12991.02 Mio. EUR
Nettogewinn:  8107.07 Mio. EUR
Gewinn je Aktie:  6.52 EUR
Schulden:  19505.89 Mio. EUR
Liquide Mittel:  6710.15 Mio. EUR
Operativer Cashflow:  9505.76 Mio. EUR
Bargeldquote:  1.04
Umsatzwachstum:  -2.78%
Gewinnwachstum:  44.67%
Dividende je Aktie:  2.77 EUR
Dividendenrendite:  2.49%
Dividendenschätzung:  2.52%
Div. Historie:  15.06.26 - 0.707578€
13.03.26 - 0.714384€
>weitere anzeigen...
Insiderhandel 3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.352.191 Euro.
Suchwörter:  GILEAD, REMDESIVIR
Letzte Datenerhebung:  26.07.26
>GILEAD Kennzahlen
Aktien/ Unternehmen:
Aktien: 1241.57 Mio. St.
Frei handelbar: 99.86%
Rückkaufquote: 0.8%
Mitarbeiter: 17000
Umsatz/Mitarb.: 1.52 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 22.64%
Bewertung:
KGV: 17.99
KGV lG: -
KUV: 5.43
KBV: 6.98
PEG-Ratio: 0.32
EV/EBITDA: 11.69
Rentabilität:
Bruttomarge: 79.41%
Gewinnmarge: 30.94%
Operative Marge: 40.41%
Managementeffizenz:
Gesamtkaprendite: 16.35%
Eigenkaprendite: 43.19%
 >GILEAD Anleihen 
>GILEAD Peer Group
 
25.07.26 - 01:45
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know (Zacks)
 
Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session....
24.07.26 - 16:57
J&J, Gilead among recipients of EU drug recommendations this week (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.07.26 - 09:45
Gileads nächste Milliardenwette rückt näher: Nach HIV jetzt HSV? (Sharedeals)
 
Seit Jahren dominiert Gilead Sciences die Virologie vor allem mit seinem milliardenschweren HIV-Geschäft. Doch hinter den Kulissen scheint der US-Pharmariese längst an der nächsten großen Franchise zu arbeiten – und die könnte Herpes simplex (HSV) heißen. Offiziell spricht Gilead bislang kaum über seine Pläne. Doch wer genauer hinsört, erkennt ein Muster: Während Investoren bisher nur […] The post Gileads nächste Milliardenwette rückt näher: Nach HIV jetzt HSV? first appeared on sharedeals.de....
23.07.26 - 22:00
Can Gilead′s Efforts to Develop New Treatments Solidify HIV Franchise? (Zacks)
 
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion....
21.07.26 - 22:06
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 (Business Wire)
 
FOSTER CITY, Calif.--(BUSINESS WIRE)--#Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2026 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.About Gilead SciencesGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.For more information on ...
21.07.26 - 17:24
Gilead Sciences, Merck Announce Findings From Phase 3 ISLEND-1 And ISLEND-2 Trials (AFX)
 
FOSTER CITY (dpa-AFX) - Tuesday, Gilead Sciences, Inc. (GILD) and Merck (MRK) announced the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials, which evaluated the safety and efficacy......
21.07.26 - 13:42
Here Are Tuesday′s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More (24/7 Wall St.)
 
Pre-Market Stock Futures: Futures are trading higher on Tuesday as traders anxiously await more positive earnings reports after a lower day on Wall Street, as chip stocks rebounded somewhat, and Iran, after 9 straight nights of U.S. attacks, had its foreign ministry indicate that discussions could be pursued further. That is a good idea, given ... Here Are Tuesday's Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More...
20.07.26 - 23:21
Gilead downgraded at Leerink on HIV PrEP headwinds (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.07.26 - 16:57
McRae Industries, Inc. Military Contract Award (PR Newswire)
 
MOUNT GILEAD, N.C., July 20, 2026 /PRNewswire/ -- McRae Industries, Inc. received a contract award from the United States Government DLA Troops Support for Navy safety toe boots. This is a firm fixed price, indefinite delivery/indefinite quantity contract that has a three-year ordering......
18.07.26 - 01:30
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
 
In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day....
17.07.26 - 02:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Gilead Sciences im Wert von 389777 USD (Insiderkauf)
 
Dickinson, Andrew D. - Vorstand - Tag der Transaktion: 2026-07-15...
17.07.26 - 02:01
Insiderhandel: Chief Comm & Corp Aff Officer verkauft Aktien von Gilead Sciences im Wert von 389758 USD (Insiderkauf)
 
Mercier, Johanna - Vorstand - Tag der Transaktion: 2026-07-15...
15.07.26 - 15:12
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? (24/7 Wall St.)
 
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look....
12.07.26 - 15:48
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. (Fool)
 
Gilead's expansion beyond HIV therapies will surprise many investors....
11.07.26 - 01:45
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts (Zacks)
 
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day....
08.07.26 - 22:18
McRae Industries, Inc. Military Contract Award and Tariff Update (PR Newswire)
 
MOUNT GILEAD, N.C., July 8, 2026 /PRNewswire/ -- On June 26, 2026, McRae Industries, Inc. received a contract award from the United States Government DLA Troops Support for Marine temperate weather combat boots. This is a firm fixed price, indefinite delivery/indefinite quantity contract......
06.07.26 - 22:00
Will the Label Expansion of Trodelvy Strengthen GILD′s Oncology Portfolio? (Zacks)
 
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy....
06.07.26 - 13:54
Here Are Monday′s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More (24/7 Wall St.)
 
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday's Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More...
03.07.26 - 00:01
Insiderhandel: Chairman & CEO verkauft Aktien von Gilead Sciences im Wert von 1894400 USD (Insiderkauf)
 
O'day, Daniel Patrick - Vorstand - Tag der Transaktion: 2026-07-01...
02.07.26 - 16:45
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
 
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Frucht eines Luxuslebens ist Luxus. - Henry David Thoreau
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!